A new campaign for Astellas Pharma’s Izervay is aimed at opening retina specialists’ eyes to the unique role they play in their geographic atrophy (GA) patients’ lives. | A new campaign for Astellas ...

Mani Foroohar, M.D., of Leerink Partners, says that the decision reflects “how sharp the departure has been between the prior ...

Bayer has cooked up the next phase of its “See Your Risks” campaign, tapping Food Network star Jeff Mauro as its sous chef. ...

It’s déjà vu all over again. Just as the kidney disease space becomes increasingly competitive, Novartis has found itself intending to turn a statistical miss into a regulatory win. | It’s déjà vu all ...

Determined to avoid a repeat of the supply shortfalls that plagued early GLP-1 rollouts for obesity, Eli Lilly has amassed a sizable store of its oral weight loss candidate orforglipron. Specifically, ...

With the writing apparently on the wall, PTC Therapeutics has called off its latest bid for FDA approval of its Duchenne muscular dystrophy (DMD) drug Translarna.  | Late Thursday, PTC revealed that ...

Eli Lilly and Innovent Biologics have deepened their ties with a new type of deal. | Eli Lilly and Innovent Biologics have ...

Cystic fibrosis (CF) specialist Vertex is tracking two newer launches that speak to its efforts to expand its prowess beyond those roots. Despite mixed early results for those rollouts so far, the ...

As Novo Nordisk’s hotly anticipated Wegovy pill gets off to the races in the U.S., the company is making sure to cover its ...

Alnylam Pharmaceuticals achieved profitability for the first time in its history in 2025. | Alnylam achieved profitability for the first time in its history in 2025. But disappointing sales ...

Supreme Group has added Broth to the mix of ad agencies it has cooked up in recent years. | Supreme Group has added Broth to the mix of ad agencies it has cooked up in recent years. Backed by a ...